Table 2.
Parameter | Baseline | Six-year follow-up |
---|---|---|
Age, years | 70 | 75 |
Height, cm | 169 | 169 |
Weight, kg | 104 | 104 |
BMI, kg/m2 | 36.46 | 36.46 |
LVEF | 60% | 60% |
sBP, mmHg | 148 | 137 |
Creatinine, µmol/L | 81 | 108 |
eGFR (CKD-EPI equation), mL/minute/1.73 m2 | 69 | 42 |
NYHA functional class | III | III |
Smoker | No | No |
Diabetes mellitus | Yes | Yes |
COPD on therapy | Yes | Yes |
HF history ≥18 months ago | Yes | Yes |
BB use | Yes | Yes |
ACEI use | Yes | Yes |
Total score, points | 22 | 26 |
Risk of 1-year mortality | 12.2% | 17.5% |
Risk of 3-year mortality | 29.2% | 39.7% |
BMI, body mass index; LVEF, left ventricular ejection fraction; sBP, systolic blood pressure (invasive); eGFR, estimated glomerular filtration rate; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; NYHA, New York Heart Association; COPD, chronic obstructive pulmonary disease; HF, heart failure; BB, beta-blocker; ACEI, angiotensin-converting enzyme inhibitor.